Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis

Neha Verma (✉ neha.verma@moffitt.org)

Internal Medicine 12902 USF Magnolia Drive Tampa, <https://orcid.org/0000-0002-4218-2346>

Muhammad Jaffer

University of South Florida College of Medicine: USF Health Morsani College of Medicine

Esha Sharda

University of South Florida College of Medicine: USF Health Morsani College of Medicine

Yolanda Pina

Moffitt Cancer Center

Asha Ramsakal

Moffitt Cancer Center

Michael Vogelbaum

Moffitt Cancer Center

Peter Forsyth

Moffitt Cancer Center

Edwin Peguero

Moffitt Cancer Center

Sepideh Mokhtari

Moffitt Cancer Center

Case report

Keywords: Nivolumab, ipilimumab, melanoma, myasthenia gravis, rituximab

Posted Date: October 15th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-91621/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Cureus on July 12th, 2021. See the published version at <https://doi.org/10.7759/cureus.16337>.

Abstract

Importance: The use of immune checkpoint inhibitors (**ICIs**) in the treatment of multiple cancers have gained prominence due to their high efficacy. However, neurological immune-related adverse events (**irAEs**) such as myasthenia gravis (**MG**) have been associated with ICI therapy. Most of these neurological irAEs are rare, and in many cases, their diagnoses and management can be challenging.

Observations: We present a case of a 70-year-old woman with Stage IIIC melanoma who developed a new onset of gradually progressive dyspnea, diplopia, and bilateral ptosis following treatment with one cycle of nivolumab and ipilimumab (**Nivo+Ipi**). She was diagnosed with MG via positive serum acetylcholine receptor (**AChR**) antibodies. She had developed a severe dyspnea at rest, which was refractory to multiple immune-suppressive therapies including prednisone, pyridostigmine, and intravenous immunoglobulin (**IVIG**). Subsequently, she was treated with rituximab 375 mg/m² monthly every 4 weeks with significant improvement of her symptoms within 48 hours each time.

Conclusions and Relevance: As the implementation of immunotherapy increases in medical practice, irAEs may become more apparent. When first-line therapies are not adequate, other alternative therapies should be explored. This case of MG as an irAE shows that rituximab can provide potential benefit to treat patients with immunotherapy-induced MG who are refractory to other standard treatments. Prospective studies are needed to further evaluate the efficacy of Rituximab irAEs.

Introduction

Immune checkpoint inhibitors (**ICIs**) have gained prominence in the treatment of a wide variety of cancers. Nivolumab (**Nivo**) is a monoclonal antibody to the programmed cell death protein-1 (**PD-1**) receptor and ipilimumab (**Ipi**) is an inhibitor of the cytotoxic T-lymphocyte-associated protein 4 (**CTLA-4**)-associated antigen. Both Nivo and Ipi (**Nivo + Ipi**) inhibit cellular signals responsible for the downregulation of the T-cell response, allowing upregulation of the immune response to target cancer cells.¹ However, several neurological immune-related adverse events (**irAEs**) have been associated with ICI use, including myasthenia gravis (**MG**) among other rare neurological syndromes.²⁻¹⁰ These syndromes are rare and difficult to diagnose, and a full neurological evaluation should not be delayed. In addition, given their rarity, their pathophysiology remains unknown and treatment options are limited to current irAE guidelines.¹

Rituximab, a monoclonal antibody to CD20, is not currently part of the guidelines to manage treatment-resistant ICI induced-MG. The only suggested treatments include pyridostigmine, corticosteroids, intravenous immunoglobulin (**IVIG**), and plasmapheresis.^{1, 11} ICI induced-MG is a rare, emerging toxicity with recent literature estimating mortality rate of approximately 30 percent.¹² We present here the second case reported in the literature for which rituximab was successfully used for ICI induced-MG.¹³ However, this is the first case to document the long term benefit of Rituximab at 375 mg/kg monthly over 14 months before patient deceased.

Case Report

A 70-year-old woman with Stage III C melanoma developed new onset dyspnea, diplopia, and bilateral ptosis two weeks following her first cycle with Nivo + Ipi. She was evaluated by a neurologist and was found to have elevated serum acetylcholine receptor (**AChR**) binding, modulating, and blocking antibodies. Her symptoms gradually worsened over the course of three cycles of Nivo + Ipi, and the ICIs were discontinued.

The patient was referred to the Neuro-Oncology clinic at H. Lee Moffitt Cancer Center (**MCC**) and Research Institute for further evaluation. The AChR antibodies were further elevated compared to a month prior. CPK level was normal. She was found to have critically low respiratory function with dyspnea at rest and was admitted to the hospital for further management. She was started on pyridostigmine 60 mg four times a day and Prednisone 90 mg daily. Given her worsening pulmonary function, she was transferred to an intensive care unit and placed on non-invasive positive pressure ventilation (NIPPV). Forced vital capacity was consistently low at approximately around 20 mL/kg. On day 2 after admission, she was started on a 5-day course of IVIG 0.4 gm/kg/day. The patient's subjective symptoms resolved, but her respiratory function tests continued to decline. On hospital day 8, she received a single dose of rituximab IV 375 mg/m² and her forced vital capacity dramatically improved within 48 hours, as illustrated in **Figure 1**. Her respiratory function continued to significantly improve, and she was subsequently discharged from the hospital. A summary of key events of the case are shown in **Figure 2**.

The patient developed worsening of her MG symptoms three to four weeks after the initial rituximab infusion; therefore, she was treated with a total of 14 more cycles of single dose of rituximab 375 mg/m² on a monthly basis, before she succumbed to her metastatic melanoma.

Discussion

Ever since their initial approval by the Federal Drug Administration (FDA) for the treatment of unresectable metastatic melanoma in 2015, the use of ICIs has rapidly expanded to include many other cancers.¹⁴ There are a number of irAEs that have been associated with ICI use, including those that produce rare and difficult to diagnose and treat neurological conditions.²⁻¹⁰ For example, multiple cases of MG associated with ICIs have been reported in the literature.^{2, 5, 6}

Guidelines for the treatment of ICI associated MG, include the use of pyridostigmine, corticosteroids, IVIG, and plasmapheresis.^{1, 11, 15} However, some patients are refractory to these treatments. Rituximab has been previously reported as a potential third-line therapy for non-ICI related MG which is refractory to standard immunosuppressive approaches.¹³ To our knowledge, our patient is the second case reported with ICI-induced MG successfully treated with rituximab.¹³

Our patient showed a dramatic improvement in her pulmonary function tests and other MG-related symptoms (dyspnea, diplopia, and ptosis) immediately after the initial therapy with rituximab IV 375

mg/m², as well as following every rituximab infusion thereafter. In this case, rituximab therapy had lasting therapeutic effects overall for three to four weeks. The optimal schedule of rituximab is unclear and published experience suggests a 375 mg/m² weekly x 4 doses.¹⁶ Nonetheless, our patient showed a marked clinical and objective improvement on a single dose given monthly. Her clinical and objective response to rituximab was consistent to the response typically seen in patients with non-ICI related MG.¹⁶

It is also possible that her clinical improvement was due to her other MG treatments, which are pyridostigmine, prednisone, and IVIG therapy, which were administered two days prior to rituximab. Certainly her favorable clinical response to rituximab could have been secondary to a delayed effect of these standard MG therapies. However, the close temporal association between clinical improvement and each rituximab infusion as well as the dramatic objective response within 48 hours of rituximab administration suggests—but don't prove—that rituximab treatment produced her dramatic recovery.

Although rituximab traditionally acts to deplete the plasma cells, recent evidence has shown that it has direct influence in the T-cell responses.¹⁷ Given this common substrate with ICIs, perhaps rituximab should be considered as a more effective therapy in ICI-induced MG compared to the traditional and standard immunosuppressive therapies.^{1, 11, 15} It is important to report similar successful cases in the literature to increase awareness about these rare neurological irAEs, and make others acquainted with the use of non-standard therapies in cases that are refractory to standard therapy. It is also important to obtain a prompt neurological consultation as soon as these types of irAEs are suspected, as these syndromes are difficult to detect and could be misdiagnosed. We suggest considering a low-dose of rituximab (375 mg/m²) as an initial therapeutic option for ICI-induced MG that is refractory to standard immunotherapies. This might help to achieve a quicker positive clinical response, avoid unnecessary hospitalizations and the serious side effects of chronic corticosteroid use.

As with any case report there are limitations to consider. We have interpreted this patient's MG to be *de novo*, and directly related to ICI administration. An alternative explanation is that the patient had preexisting asymptomatic MG (i.e., with positive AChR antibodies) and treatment with Nivo + Ipi unmasked her condition. Also, while we observed an excellent and reproducible response to rituximab, prospective studies will be needed to definitively evaluate the efficacy of rituximab in ICI-induced MG. Establishing an animal model of ICI-associated MG may also suggest mechanistic and therapeutic interventions. However, given the rarity of this condition, including in both non-immunotherapy and immunotherapy induced cohorts, it may be challenging to complete prospective clinical studies needed to prove efficacy of this approach. Further evaluation with prospective studies looking at AChR antibodies pre and post ICI treatment may be useful to help establish the biological basis for ICI-induced MG.

Conclusion And Future Directions

This case report suggests that rituximab may be an effective alternative or addition to the standard treatments for ICI-induced MG refractory to current standard immunosuppressive therapies. As the use of ICIs is rapidly increasing to treat a variety of malignancies, more neurological irAEs are expected to occur,

including rare neurological conditions that are difficult to manage and can be resistant to current treatments per AE guidelines.^{1, 11, 15} Future prospective clinical studies regarding the safety profile, optimal dosing, and effectiveness of rituximab in patients with ICI-induced MG presents an exciting route of inquiry.

Declarations

Ethics approval and consent to participate Not Applicable

Consent for publication: Patient has been consented

Availability of data and material: Not Applicable

Competing interests: Authors have no competing interests

Funding: Not Applicable

Authors' contributions: Authors' contributions were writing, revising and chart reviewing.

Acknowledgements: Not applicable

References

1. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2018;36:1714-1768.
2. Chen YH, Liu FC, Hsu CH, Chian CF. Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report. *Medicine (Baltimore)* 2017;96:e7350.
3. Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. *Eur J Cancer* 2017;73:1-8.
4. Johansen A, Christensen SJ, Scheie D, Hojgaard JLS, Kondziella D. Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review. *Neurology* 2019;92:663-674.
5. Kang KH, Grubb W, Sawlani K, et al. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management. *Am J Otolaryngol* 2018;39:642-645.
6. Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. *Cancer Sci* 2016;107:1055-1058.
7. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. *Neuro Oncol* 2014;16:589-593.

8. Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment. *Journal of the peripheral nervous system* : JPNS 2019;24 Suppl 2:S74-S85.
9. Supakornnumporn S, Katirji B. Guillain-Barre Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review. *J Clin Neuromuscul Dis* 2017;19:80-83.
10. Yildirim N, Gonen M, Balgetir F, Er MB. Fatal Acute Motor Axonal Neuropathy Induced by Nivolumab: A Case Report and Literature Review. *Clin Genitourin Cancer* 2019;17:e1104-e1107.
11. Haanen J, Carbone F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017;28 Suppl 4:iv119-iv142.
12. Zebardast N, Patwa HS, Novella SP, Goldstein JM. Rituximab in the management of refractory myasthenia gravis. *Muscle Nerve* 2010;41:375-378.
13. Crusz SM, Radunovic A, Shepherd S, et al. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis. *Eur J Cancer* 2018;102:49-51.
14. Alexander W. The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge. *P T* 2016;41:185-191.
15. (DCTD) NCIDoCTaD. Common Terminology Criteria for Adverse Events (CTCAE4). 2018.
16. Tandan R, Hehir MK, 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. *Muscle Nerve* 2017;56:185-196.
17. Marino M, Bartoccioni E, Alboini PE, Evoli A. Rituximab in myasthenia gravis: a "to be or not to be" inhibitor of T cell function. *Ann N Y Acad Sci* 2018;1413:41-48.

Figures

Pulmonary Function Test Parameters vs. Hospital Day

Figure 1

Pulmonary function parameters with Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF) and treatments for irAEs. The pulmonary function parameters throughout the hospital visit are shown with Forced Vital Capacity (FVC) and Negative Inspiratory Force (NIF). The patient was initially treated with pyridostigmine 60 mg four times a day and prednisone 90 mg daily, followed by IVIG 2 mg/kg (divided into 5 days). Her FVCs were consistently low at around 20 mL/kg for 8 days including 2 days after completion of IVIG. Subsequently, she received treatment with a single infusion of rituximab IV 375 mg/m² and within one day post-treatment, her FVCs started to show a marked improvement reaching >100 mL/kg at day 11. There is a significant improvement in the patient's FVCs and stabilization of her NIF after the administration of a single dose of rituximab IV 375 mg/m². NIF taken as an absolute value function with normal values < -60 cm H₂O. Abbreviations: IVIG = intravenous immunoglobulin; FVC/kg = Forced Vital Capacity/Ideal Body Weight in kilograms; NIF = Negative Inspiratory.

Figure 2

Summary timeline of treatment and clinical symptoms. The patient developed MG-like symptoms two weeks following cycle 1 of Nivo + Ipi. Her symptoms gradually progressed and Nivo + Ipi were discontinued after cycle 3. She was found to be in MG crisis on week 16. She was sequentially treated with pyridostigmine 60 mg four times a day and Prednisone 90 mg daily on week 16 and IVIG 2 gm/kg (divided into 5 days) on week 16 day 2 with no objective improvement in her pulmonary function tests, which were consistently low at 20 mL/kg. She was transferred to the ICU for NIPPV and received treatment with a single infusion of rituximab IV 375 mg/m² on week 17 day 1 with significant improvement in her symptoms including pulmonary function tests showing >100 mL/kg. She was eventually discharged from the hospital on week 17 day 5. Abbreviations: Nivo + Ipi = Nivolumab and Ipilimumab; IVIG = intravenous immunoglobulin; NIPPV = non-invasive positive pressure ventilation.